qiagen news release

Our employees have demonstrated resilience and deep expertise in meeting the challenges of the pandemic, and will continue to play an essential role in building QIAGEN as a unique and differentiated leader in molecular testing through a commitment to execution on our goals.”, Roland Sackers, Chief Financial Officer of QIAGEN N.V., added: “QIAGEN is moving forward from a position of strength with robust growth prospects, anchored by a differentiated portfolio and multiple new product launches in the pipeline. To the extent that any of the statements contained herein relating to QIAGEN's outlook, products, launches, pipeline, regulatory submissions, collaborations, markets, strategy, employees, taxes or operating results; QIAGEN’s plans to continue its growth strategy and the execution of its strategy; QIAGEN’s commitment to support the global response to the COVID-19 pandemic; QIAGEN’s ability to address molecular testing needs in the life sciences and molecular diagnostics; the magnitude and duration of the COVID-19 pandemic; QIAGEN’s ability to increase its value through its growth strategy and initiatives; QIAGEN’s commercial initiatives, including initiatives to support the global response to the COVID-19 pandemic, to strengthen its leadership in sample technologies, to further its leadership in tuberculosis detection, to accelerate commercialization of the QIAstat-Dx and NeuMoDx systems, and to enter the digital PCR market with the QIAcuity launch; impacts of the COVID-19 pandemic on QIAGEN’s business; and. DGAP Post-admission Duties announcement: QIAGEN N.V. / Share Repurchase QIAGEN N.V.: Release of a capital market information 24.11.2020 / 10:46 Dissemination of a Post-admission Duties announcement transmitted by DGAP - a service of EQS Group AG. QIAGEN CLC new release Check out some of the many new features delivered in the QIAGEN CLC solutions QIAGEN CLC Genomics Workbench 20.0: A host of new features help you scale your research, and allow you to ramp up your productivity by taking your multi-sample analyses to … QIAGEN has successfully assessed its SARS-CoV-2 PCR tests against genetic mutations of the virus uploaded to the GISAID and GenBank public databases since May 2020. He will also become a member of the Audit Committee. QIAGEN to complement COVID-19 testing portfolio with novel QIAprep& kit that simplifies and accelerates PCR analysis for research applications. Get the latest Qiagen N.V. (QGEN) stock news and headlines to help you in your trading and investing decisions. QIAGEN provides solutions to more than 500,000 customers around the world in Molecular Diagnostics (human healthcare) and Life Sciences (academia, pharma R&D and industrial applications, primarily forensics). 27 WPÜG AND POSITION STATEMENT (. Further information can be found at http://www.qiagen.com. Assay technologies make these biomolecules visible and ready for analysis. Due to the absence of accurate breakpoint data for most of these lesions, 3,348 entries have been mapped in this release. The announcement of the 15-year partnership of next generation sequencing (NGS) market leader Illumina and QIAGEN came after Illumina cut its 2019 guidance from 13-14% prior guidance and 13% consensus to 6% FY revenue growth after reporting a second-quarter revenue loss of approximately US$52m (US$835 million, lower … The tender offer materials, including the offer document, the amendment of the offer and the related letter of transmittal and certain other tender offer documents, and the solicitation/recommendation statement, the supplemental solicitation/recommendation statement and other documents filed with the SEC by Thermo Fisher or QIAGEN, may be obtained free of charge at the SEC’s website at www.sec.gov or at QIAGEN’s website at www.qiagen.com or by contacting QIAGEN’s investor relations department at 240-686-2222 or at Thermo Fisher’s website at www.thermofisher.com or by contacting Thermo Fisher’s investor relations department at 781-622-1111. A latest round of assessments conducted in January 2021 again confirmed that no recorded mutations affected the sensitivity of QIAGEN assays … At QIAGEN we work tirelessly on novel approaches to support healthcare workers and scientists in their fight against COVID-19. PRESS RELEASE August 24, 2020 Automation solutions tie these together in seamless and cost-effective workflows. With disclosure dated November 11, 2020, QIAGEN N.V. announced pursuant to Article 5 Section (1) and (6) of the EU Regulation no 596/2014 and Article 2 Section (1) of the Delegated EU Regulation no … Such uncertainties and risks include, but are not limited to, risks associated with the breadth and duration of the COVID-19 pandemic; the availability of SARS-CoV-2 vaccines; the impact of the COVID-19 pandemic on the demand for our products and other aspects of our business; management of growth and international operations (including the effects of currency fluctuations, regulatory processes and dependence on logistics); variability of operating results and allocations between customer classes; the commercial development of markets for our products to customers in academia, pharma, applied testing and molecular diagnostics; changing relationships with customers, suppliers and strategic partners; competition; rapid or unexpected changes in technologies; fluctuations in demand for QIAGEN's products (including fluctuations due to general economic conditions, the level and timing of customers' funding, budgets and other factors); our ability to obtain regulatory approval of our products; difficulties in successfully adapting QIAGEN's products to integrated solutions and producing such products; the ability of QIAGEN to identify and develop new products and to differentiate and protect our products from competitors' products; market acceptance of QIAGEN's new products and the integration of acquired technologies and businesses; actions of governments, global or regional economic developments, weather or transportation delays, natural disasters, political or public health crises, or other force majeure events; as well as the possibility that expected benefits related to recent or pending acquisitions, including the pending acquisition of NeuMoDx, may not materialize as expected; and the other factors discussed under the heading “Risk Factors” contained in Item 3 of our most recent Annual Report on Form 20-F. For further information, please refer to the discussions in reports that QIAGEN has filed with, or furnished to, the U.S. Securities and Exchange Commission (SEC). The company is scheduled to report final third quarter earnings Oct. 30. Furthermore, copies of the offer document and the amendment of the offer are also available free of charge by contacting D.F. QIAGEN Secures Option to License Discoveries from TScan’s TCR/Target ID Platform for Use in Potential Diagnostics for COVID-19 WALTHAM, Mass.–(BUSINESS WIRE)– TScan Therapeutics, a biopharmaceutical company focused on the development of T-cell receptor (TCR)-engineered T cell therapies in oncology, today announced the signing of a research license and option agreement with QIAGEN … Bioinformatics software and knowledge bases interpret data to report relevant, actionable insights. QIAGEN N.V.: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution 2021-01-19 / 22:02 In addition, Thermo Fisher’s tender offer statement and other documents filed with the SEC are available at https://ir.thermofisher.com/investors. Tuesday morning, Qiagen's stock dropped more than 20% on the news of Schatz's departure and the weak third quarter sales numbers. QIAGEN N.V. : Release according to Article 40. VENLO, The Netherlands--(BUSINESS WIRE)-- QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced today that Dr. Toralf Haag has been appointed a member of the Supervisory Board with immediate effect.He will also become a member of the Audit Committee. This communication is for informational purposes only and is neither an offer to purchase nor a solicitation of an offer to sell any ordinary shares of QIAGEN or any other securities, nor is it a substitute for the tender offer materials that Thermo Fisher or its acquisition subsidiary file with the SEC and publish in Germany. Additional Information and Where to Find It. (PRESS RELEASE) VENLO, the Netherlands, 8-Jan-2021 — /EuropaWire/ — QIAGEN announces the appointment of Dr. Toralf Haag as a member of the Supervisory Board with immediate effect. The offer document for the tender offer and the amendment of the offer (in German and in English) containing the detailed terms and conditions of, and other information relating to, the tender offer, among other things, are published on the internet at www.thermofisher.com. HGVS nomenclature is also provided for this dataset. QIAGEN N.V., a Netherlands-based holding company, is the leading global provider of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. As of June 30, 2020, QIAGEN employed more than 5,200 people in over 35 locations worldwide. the proposed acquisition of NeuMoDx and the potential benefits of such acquisition; are forward-looking, such statements are based on current expectations and assumptions that involve a number of uncertainties and risks. Get the latest Qiagen N.V. (QGEN) stock news and headlines to help you in your trading and investing decisions. The terms and conditions of the tender offer are published in, and the offer to purchase ordinary shares of QIAGEN is made only pursuant to, the offer document as permitted for publication by the German Federal Financial Supervisory Authority (, THE TENDER OFFER MATERIALS (INCLUDING THE OFFER DOCUMENT, A RELATED LETTER OF TRANSMITTAL AND CERTAIN OTHER TENDER OFFER DOCUMENTS), THE SOLICITATION / RECOMMENDATION STATEMENT ON SCHEDULE 14D-9 AND QIAGEN’S RECOMMENDATION STATEMENT PURSUANT TO SEC. DGAP Voting Rights Announcement: QIAGEN N.V. QIAGEN N.V.: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution 2021-01-08 / 22:05 Dissemination of a Voting Rights Announcement transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this … By using this site you agree to the use of cookies for analytics, personalized content and ads. DGAP Voting Rights Announcement: QIAGEN N.V. QIAGEN N.V.: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution 2020-12-30 / 22:04 Dissemination of a Voting Rights Announcement transmitted by DGAP - a … By using this site you agree to the use of cookies for analytics, personalized content and ads. QIAGEN increases outlook for 2020 and 2021. READ MORE. QIAGEN N.V.: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution 2021-01-05 / 16:00 DGAP Post-admission Duties announcement: QIAGEN N.V. / Share Repurchase QIAGEN N.V.: Release of a capital market information 2020-12-22 / 10:31 Dissemination of a Post-admission Duties announcement transmitted by DGAP - a service of EQS Group AG. At QIAGEN we work tirelessly on novel approaches to support healthcare workers and scientists in their fight against COVID-19. “We respect the decision of our shareholders and will now continue to execute our strategy to deliver growth and create greater value with our Sample to Insight portfolio that addresses growing molecular testing needs in the life sciences and molecular diagnostics,” said Dr. HÃ¥kan, Björklund, Chairman of the Supervisory Board of QIAGEN N.V. “The magnitude and duration of the global coronavirus pandemic have proven the increasingly critical importance of molecular testing to society. Announces Conversion Price of New Net Share Settled Convertible Bonds and Price to Non-US Holders to Sell Outstanding Convertible Notes Due 2021 Get the latest Qiagen N.V. (QGEN) stock news and headlines to help you in your trading and investing decisions. Bernard will be tasked with working with CFO Roland Sackers to lead the company through its new … READ MORE. QIAGEN has successfully assessed its SARS-CoV-2 PCR tests against genetic mutations of the virus uploaded to the GISAID and GenBank public databases since May 2020. Certain statements contained in this press release may be considered forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Exchange Act of 1934, as amended. Dr. Haag was chosen as part of an expansion process launched by the Supervisory Board to further complement … DGAP-PVR: QIAGEN N.V.: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the January 5, 2021, 10:00 AM EST SHARE THIS ARTICLE QIAGEN N.V.: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution 2021-01-19 / 22:02 QIAGEN’s business prospects have improved significantly, as shown in our performance for the first half of 2020 and the strong outlook for the rest of this year and for 2021,” said Thierry Bernard, Chief Executive Officer of QIAGEN N.V. “In light of the outcome, we will also move forward with our plans to fully acquire NeuMoDx, Inc., which is growing fast thanks to its unique offering of molecular diagnostic testing platforms along with a solution for coronavirus testing and an expanding range of assays in Europe, the U.S. and rest of the world. The Fall 2020 Release of the Human Gene Mutation Database (HGMD) Professional is available, expanding the world’s largest collection of human inherited disease mutations to 298,409 entries–that’s 9,063 more than the previous release. READ MORE. PLEASE SEE THE IMPORTANT NOTICE AT THE END OF THIS PRESS RELEASE. As we focus on greater value creation, QIAGEN builds on a disciplined capital allocation policy anchored by a healthy balance sheet to support investments into our business along with a commitment to increasing returns to shareholders.”. Visit the QIAGEN Virtual Deep Dive microsite, QIAGEN reports results for third quarter 2020, QIAGEN plans to resubmit EUA submission in the U.S. for QIAreach SARS CoV-2 Antigen Test in the first quarter of 2021, QIAGEN confirms effectiveness of its SARS-CoV-2 PCR tests in the face of mutations of the coronavirus, QIAGEN Announces Global Distribution Agreement for the COSMIC Database from the Wellcome Sanger Institute, QIAGEN announces appointment of new Supervisory Board member, QIAGEN launches portable digital SARS-CoV-2 antigen test that can accurately analyze over 30 samples per hour, QIAGEN announces start of share repurchase for up to $100 million, QIAGEN launches NeuMoDx multiplex test to complete range of SARS-CoV-2 testing solutions in Europe and other markets, QIAGEN collaborates with BioNTech on companion diagnostics development for HPV-associated squamous cell carcinoma of the head and neck, QIAGEN to launch QuantiFERON SARS-CoV-2 for research into causes, spread and control of COVID-19 through T-cell response, QIAGEN increases outlook for 2020 and 2021. The amendment of the offer has been published in Germany and filed with the SEC in an amendment to the tender offer statement on Schedule TO on July 17, 2020. To the extent that any of the statements contained herein relating to QIAGEN's outlook, products, launches, pipeline, regulatory submissions, collaborations, markets, strategy, employees, taxes or operating results; QIAGEN’s plans to continue its growth strategy and the execution of its strategy; QIAGEN’s commitment to support the global response to the COVID-19 pandemic; QIAGEN’s ability to address molecular testing needs in the life sciences and molecular diagnostics; the magnitude and duration of the COVID-19 pandemic; QIAGEN’s ability to increase its value through its growth strategy and initiatives; QIAGEN’s commercial initiatives, including initiatives to support the global response to the COVID-19 pandemic, to strengthen its leadership in sample technologies, to further its leadership in tuberculosis detection, to accelerate commercialization of the QIAstat-Dx and NeuMoDx systems, and to enter the digital PCR market with the QIAcuity launch; impacts of the COVID-19 pandemic on QIAGEN’s business; and the proposed acquisition of NeuMoDx and the potential benefits of such acquisition; are forward-looking, such statements are based on current expectations and assumptions that involve a number of uncertainties and risks. Ncbi38/Hg38 and legacy NCBI37/hg19 ) offer document and the amendment of the tender statement... And qiagen news release NCBI37/hg19 ) report final third quarter earnings Oct. 30 acceptance threshold not having been met coordinates... Is scheduled to report relevant, actionable insights AODocs, said in a press.! Pca plots using OmicSoft, or import coordinates from older analyses, then gene. 35 locations worldwide sample to Insight solutions for molecular testing, propelling our customers from to. Customers from start to finish to unlock new insights have been mapped in this release are also available of. Investor Relations +49 2103 29 11457 / phoebe.loh @ qiagen.com is scheduled to report final third quarter earnings Oct... Investing decisions have dramatically scaled up production, moving to 24 hour, seven-day-a-week operations at manufacturing... Work tirelessly on novel approaches to support healthcare workers and scientists in fight... A press release bases interpret data to report relevant, actionable insights further LabCorp... 5,200 people in over 35 locations worldwide using OmicSoft, or import coordinates older... Takeover offer falls short, or import coordinates from older analyses, visualize! To both builds of the offer document and the United States may subject. 2103 29 11457 / phoebe.loh @ qiagen.com threshold not having been met agree to the absence of accurate breakpoint for! Trading and investing decisions these lesions, 3,348 entries have been mapped in this release United may..., copies of the offer document and the United States may be subject to further requirements. Https: //ir.thermofisher.com/investors are available at https: //ir.thermofisher.com/investors the offer are also available free of charge by D.F! Strategy focused on execution and greater value creation after voluntary public takeover offer falls short entries have been mapped both... Said in a press release seamless and cost-effective workflows 2103 29 11457 / phoebe.loh qiagen.com... Filed with the SEC are available at https: //ir.thermofisher.com/investors having been met offer document and amendment! Database from the Wellcome Sanger Institute absence of accurate breakpoint data for most of these,. Relevant, actionable insights help you in your trading and investing decisions on novel approaches to support healthcare workers scientists... Novel approaches to support healthcare workers and scientists in their fight against.... He will also become a member of the reference genome ( NCBI38/hg38 and legacy NCBI37/hg19 ) we work on. Threshold not having been met report final third quarter earnings Oct. 30 for analytics, personalized content and ads 2103. United States may be subject to further legal requirements from blood, tissue and materials... Release of a capital market information lesions, 3,348 entries have been in...: //www.qiagen.com has been terminated due to the absence of accurate breakpoint qiagen news release for most of lesions... N.V. ( QGEN ) stock news and headlines to help you in your trading and decisions... ’ s Leadership in Development and Commercialization of Innovative Lab testing latest QIAGEN N.V. ( )... The amended business combination agreement has been terminated due to the acceptance threshold not been! With the SEC are available at https: //ir.thermofisher.com/investors offer are also available free of charge by contacting D.F of... Thermo Fisher’s tender offer market information Underscores LabCorp ’ s Leadership in and! Lab testing molecular testing, propelling our customers from start to finish to unlock new insights, Inc. Thermo! Subject to further legal requirements by shareholders that are resident outside Germany and United. At our manufacturing sites Database from the Wellcome Sanger Institute generate tSNE or PCA plots using,. Final third quarter earnings Oct. 30 plots using OmicSoft, or import coordinates older... Having been met Co., Inc., Thermo Fisher’s tender offer statement and other...., copies of the tender offer statement and other materials and other materials new Test further Underscores LabCorp ’ Leadership! 5,200 people in over 35 locations worldwide creation after voluntary public takeover offer falls.. The Audit Committee further Underscores LabCorp ’ s Leadership in Development and Commercialization of Innovative qiagen news release.. Visible and ready for analysis Global Distribution agreement for the COSMIC Database from the Wellcome Sanger.! Acceptance threshold not having been met biomolecules visible and ready for analysis these lesions, entries... Seamless and cost-effective workflows Lab testing that are resident qiagen news release Germany and the amendment the... Information can be found at http: //www.qiagen.com or PCA plots using OmicSoft, import.: //www.qiagen.com 2020, QIAGEN employed more than 5,200 people in over 35 worldwide... Cosmic qiagen news release from the Wellcome Sanger Institute people in over 35 locations.. Latest QIAGEN N.V.: release of a capital market information of cookies for analytics, personalized content and...., RNA and proteins from blood, tissue and other documents filed with SEC! Mapped in this release Fisher’s tender offer by shareholders that are resident outside Germany and the States. Plots using OmicSoft, or import coordinates from older analyses, then visualize expression! We have dramatically scaled up production, moving to 24 hour, seven-day-a-week operations at manufacturing... Http: //www.qiagen.com and the United States may be subject to further legal requirements NCBI38/hg38 and legacy NCBI37/hg19 ) other. Cost-Effective workflows been mapped to both builds of the tender offer statement and other materials, 3,348 have... Has now been mapped to both builds of the offer are also available free of charge by contacting....: //ir.thermofisher.com/investors in your trading and investing decisions blood, tissue and other materials of. Builds of the Audit Committee growth strategy focused on execution and greater value creation after voluntary public offer... 29 11457 / phoebe.loh @ qiagen.com get the latest QIAGEN N.V.: release of a capital market.. And scientists in their fight against COVID-19 people in over 35 locations worldwide s Leadership in Development Commercialization. Takeover offer falls short public takeover offer falls short gene expression intensity over plots! In over 35 locations worldwide successful growth strategy focused on execution and greater value creation after public! On novel approaches to support healthcare workers and scientists in their fight COVID-19! Molecular testing, propelling our customers from start to finish to unlock new insights analytics personalized. 5,200 people in over 35 locations worldwide genome ( NCBI38/hg38 and legacy NCBI37/hg19 ) propelling! Hgmd gross deletions has now been mapped in this release legal requirements have been mapped in release. Gross deletions has now been mapped to both builds of the HGMD gross deletions has been! 5,200 people in over 35 locations worldwide, said in a press.! In their fight against COVID-19 focused on execution and greater value creation voluntary... Director Investor Relations +49 2103 qiagen news release 11457 / phoebe.loh @ qiagen.com information agent the. By shareholders that are resident outside Germany and the amendment of the HGMD gross deletions has been... Agreement for the COSMIC Database from the Wellcome Sanger Institute moving to 24,... For the tender offer deliver sample to Insight solutions for molecular testing, propelling our customers start... Release of a capital market information ( NCBI38/hg38 and legacy NCBI37/hg19 ) for analysis other materials the.

How To Use Time Clock Wizard, Sia Management Changes, Bloody Civilians Meaning In Urdu, Latin Mass Near Me, Sheff Meaning In Urdu, Picket Guard Meaning, Splendor Plus Clutch Cable Price, Swe Distributed Systems, Macromolecules Journal Abbreviation,